Irene Ghobrial, MD
Dana-Farber Cancer Institute
Harvard Medical School
Dr. Irene Ghobrial received her medical degree from Cairo University School of Medicine, Egypt. She completed her internal medicine training at Wayne State University, and her hematology/oncology subspecialty training at Mayo Clinic College of Medicine. She is currently a Professor at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, and an Associate Member of the Broad Institute, Cambridge. Dr. Ghobrial is also Director of the Clinical Investigator Research Program at DFCI, Co-director of the Center for Prevention of Progression (CPOP), and Co-leader of the Blood Cancer Research Partnership (BCRP). In addition, she is the Director of the Michele & Stephen Kirsch Laboratory.
Dr. Ghobrial’s research focuses on understanding mechanisms of tumor progression from early precursor conditions, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma (MM) and Waldenström macroglobulinemia (WM). She specifically focuses on the role of the malignant bone marrow niche in regulating disease progression. Dr. Ghobrial is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored/co-authored over 250 publications and book chapters and has received funding support from the National Cancer Institute (NCI) as well as multiple foundations including Stand Up to Cancer, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, and the International Myeloma Foundation. She has received multiple awards including the Ken Anderson Young Investigator Award, Robert A. Kyle Award for Research in Waldenström Macroglobulinemia, and Mentor of the Year Award at DFCI.